Related Experiment Video

Updated: Aug 31, 2026

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

Apolipoprotein E genotype does not influence the progression of multiple sclerosis

Giovanni Savettieri1, Virginia Andreoli, Simona Bonavita

  • 1Institute of Neuropsychiatry, University of Palermo, Palermo, Italy.

Journal of Neurology
|September 25, 2003
PubMed
Abstract

Insights

The apolipoprotein E (APOE) epsilon4 allele and the -491 A/T promoter polymorphism do not appear to influence the progression of multiple sclerosis (MS). This study found no association between these APOE variations and a faster disease course in MS patients.

Area of Science:

  • Neuroimmunology
  • Genetics
  • Neurology

Background:

  • Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system.
  • Genetic factors, including apolipoprotein E (APOE) polymorphisms, are investigated for their role in MS pathogenesis and progression.
  • Understanding genetic associations can inform disease management and therapeutic strategies.

Purpose of the Study:

  • To examine the relationship between apolipoprotein E (APOE) gene polymorphisms and the rate of disease progression in individuals with multiple sclerosis (MS).
  • To determine if specific APOE variants, namely the epsilon4 allele and the -491 A/T promoter polymorphism, are associated with clinical characteristics and disability progression in MS.

Main Methods:

  • A cohort of 428 patients with clinically defined MS and a disease duration of at least three years was analyzed.
  • Data collected included age at onset, clinical type, disease duration, and disability assessed by the Expanded Disability Status Scale (EDSS).
  • Progression Index (PI) was calculated to quantify disease progression, alongside APOE genotyping and analysis of the -491 A/T promoter polymorphism.

Main Results:

  • No statistically significant association was found between the APOE epsilon4 allele and the clinical characteristics of the MS study population.
  • Analysis of the -491 A/T APOE promoter polymorphism in 236 MS subjects also revealed no association with the selected clinical variables.
  • These findings indicate that the investigated APOE polymorphisms do not correlate with disease severity or progression markers in this cohort.

Conclusions:

  • The APOE epsilon4 allele is not associated with a more rapid disease course in the studied population of multiple sclerosis patients.
  • The -491 A/T APOE promoter polymorphism also does not appear to influence the progression rate or clinical outcomes in MS.
  • These genetic variations may not be significant determinants of disease progression in multiple sclerosis.

More Related Videos

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis05:44

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis

Published on: October 13, 2023

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Genetic Lingo02:25

Genetic Lingo

An organism is diploid if it inherits two variants, or alleles, of each gene, one from each parent. These two alleles constitute the genotype for a given gene. The term genotype is also used to refer to an organism’s complete set of genes. A diploid organism with two identical alleles has a homozygous genotype, whereas two different alleles indicate a heterozygous genotype. Observable traits arising from genotypes are called phenotypes, which can also be influenced by environmental factors. An...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...